In order to consider that a treatment for prostate cancer is efficient, nadir PSA gives a good indication, but the PSA stability is even more important: a low and stable PSA level evidences the absence of cancerous disease (stability being defined in accordance with the ASTRO criteria). In Munich, 104 T1-T2 patients(1) treated with the standard treatment parameters are now available for PSA stability assessment (at least 1 year follow-up): 88,9% of the patients were presenting with a stable PSA level after Ablatherm. More than 60% of the patients presented an undetectable nadir PSA after the Ablatherm-HIFU treatment

(1) EDAP Technomed, 2001